Breaking Finance News

Argus downgraded Allergan (NYSE:AGN) from Buy to Hold in a statement released earlier today.

Argus has downgraded Allergan (NYSE:AGN) from Buy to Hold in a statement released on Thursday December 07, 2017.

Having a price of $177.23, Allergan (NYSE:AGN) traded -0.52% lower on the day. With the last close down -18.27% from the two hundred day average, compared with the S&P 500 Index which has maintained over the same period. Allergan has recorded a 50-day average of $211.30 and a two hundred day average of $230.36. Volume of trade was up over the average, with 4,755,555 shares of AGN changing hands over the typical 2,808,180

See Chart Below

Allergan (NYSE:AGN)

Allergan has a 52 week low of $182.80 and a 52 week high of $256.80 with a PE ratio of 5.74 Allergan’s market capitalization is currently $0.

In addition to Argus reporting its stock price target, a total of 16 brokerages have issued a ratings update on the company. The average stock price target is $293.75 with 7 brokerages rating the stock a strong buy, 11 brokerages rating the stock a buy, 2 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell.

Brief Synopsis On Allergan (NYSE:AGN)

Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, womenÂ’s health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as AlzheimerÂ’s disease. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. In addition, the company distributes generic and branded pharmaceutical products primarily to independent and chain pharmacies, nursing homes, mail order pharmacies, hospitals, clinics, and physician offices. Further, it develops a portfolio of breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. The company has licensing agreement with Assembly Biosciences, Inc.; Mimetogen Pharmaceuticals, Inc.; Almirall, S.A; Naurex, Inc.; and Merck & Co. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.